Skyhawk Therapeutics has entered a substantial collaboration with Merck KGaA, targeting neurological diseases through RNA splicing modulation with an agreement worth up to $2 billion. The partnership leverages Skyhawk’s SkySTAR platform to discover small molecule RNA-targeted drugs, with Merck KGaA holding rights to clinical development and commercialization. This deal marks a continued expansion of RNA-targeting strategies in drug discovery, focusing on difficult neurological targets. Skyhawk’s ongoing pipeline includes splicing modulators for Huntington’s disease and preclinical programs in lymphoma and fibrosis.